It is likely that active components of SLD act through targets to jointly regulate signaling pathways involved in lipid and atherosclerosis, the PI3K-Akt signaling pathway, immune-related signaling pathways, and pathways in cancer to improve patient outcomes (Figure 7A). This evidence concerns the gene AKT1 and atherosclerosis.